

RhoE controls myoblast alignment prior fusion through RhoA and ROCK

Running title: RhoE is a regulator of myoblast fusion

Mathieu Fortier, Franck Comunale, Jérôme Kucharczak, Anne Blangy, Sophie Charrasse and
Cécile Gauthier-Rouvière*

Universités Montpellier 2 et 1, CRBM, CNRS, UMR 5237, IFR 122 1919 Route de Mende,
34293 Montpellier, France.

*Corresponding author: cecile.gauthier@crbm.cnrs.fr

Tel: 33467613355

Fax: 33467521559

Abstract

Differentiation of skeletal myoblasts into multinucleated myotubes is a multi-step process orchestrated by several signaling pathways. The Rho small G protein family plays critical roles both during myogenesis induction and myoblast fusion.

We report here that, in C2C12 myoblasts, expression of RhoE, an atypical member of this family, increases until the onset of myoblast fusion before resuming its basal level once fusion has occurred. We show that RhoE accumulates in elongated, aligned myoblasts prior fusion and that its expression is also increased during injury-induced skeletal muscle regeneration. Moreover, although RhoE is not required for myogenesis induction, it is essential for myoblast elongation and alignment before fusion and for M-cadherin expression and accumulation at the cell-cell contact sites. Myoblasts lacking RhoE present defective p190RhoGAP activation and RhoA inhibition at the onset of myoblast fusion. RhoE interacts also with the RhoA effector ROCK1, whose activity must be down-regulated to allow myoblast fusion. Consistently, we show that pharmacological inactivation of RhoA or ROCK restores myoblast fusion in RhoE deficient myoblasts.

RhoE physiological up-regulation before myoblast fusion is responsible for the decrease in RhoA and ROCK1 activities, which are required for the fusion process. Therefore, we conclude that RhoE is an essential regulator of myoblast fusion.

Key words :RhoE, myoblast fusion, RhoA, ROCK

Abbreviations : DM: differentiation medium, GAPs: GTPase-activating proteins, GEFs: guanine nucleotide-exchange factors, GM: growth medium, MLCK: myosin light chain kinase, ROCK: Rho-associated kinase

Introduction

The Rho family of Ras-like GTPases consists of signaling molecules involved in cytoskeleton remodeling, membrane recycling and gene transcription. Rho GTPases play essential roles in controlling cell adhesion, migration, cell proliferation and differentiation (1) and particularly, in skeletal myogenesis (2-10). The Rho subfamily contains 21 members clustered in four subgroups that comprise RhoA, RhoB and RhoC; Rnd1, Rnd2 and Rnd3/RhoE; RhoBTB1, RhoBTB2 and RhoBTB3; and Rac1, Rac2, Rac3, Cdc42, TC10, TCL, RhoG, Chp1 and Chp2/Wrch-1. The remaining proteins (RhoD, Rif and RhoH/TTF) delineate distinct stems in the phylogenetic tree. Rho GTPases act as molecular switches that convert extracellular signals into multiple cellular effects by cycling between an inactive GDP-bound and an active GTP-bound state. Their activation is controlled by guanine nucleotide-exchange factors (GEFs), whereas their inactivation is promoted by GTPase-activating proteins (GAPs). The members of the Rnd subfamily (Rnd1, Rnd2 and Rnd3 also called RhoE) and RhoH are an exceptions since they are always bound to GTP, are not regulated by GEFs and GAPs and have very low, if any, intrinsic GTPase activity (11-14). Although 21 members are known in mammals, only few of them have been studied extensively. In skeletal muscle cells, the role of RhoA, Rac1 and TC10 has been analyzed. RhoA and Rac1 act both in myogenesis induction and myoblast fusion. RhoA positively regulate MyoD expression and skeletal muscle cell differentiation, as it is required for serum response factor (SRF)-mediated activation of several muscle-specific gene promoters (2). Conversely, Rac1 inhibits myogenesis induction by preventing myoblast withdrawal from the cell cycle (3, 15). Later on during the skeletal muscle differentiation program and in contrast to its inhibitory role in myogenesis induction, Rac1 signaling is involved in myoblast fusion in *Drosophila* (4-7, 16). Recently, we demonstrated that Rac1 activity is required for myotube formation (17), whereas RhoA activity must be down-regulated during this process (8, 9, 18), as that of the Rho-

associated kinase ROCK1, an effector of RhoA (9, 18). In analyzing the potential mechanisms that might be involved in down-regulation of RhoA and ROCK1 during myoblast fusion, we focused on RhoE. Indeed, RhoE is ubiquitously expressed and is believed to be a RhoA and ROCK1 antagonist (19). RhoE was isolated in a two-hybrid screen that used p190RhoGAP as bait (11) and shown to stimulate p190RhoGAP-mediated GAP activity toward RhoA (20). Moreover, RhoE binds and inhibits ROCK I activity (21). Here we show, that RhoE is involved in mammalian myoblasts fusion in the myogenic cell line C2C12. We demonstrate that RhoE expression increases until the onset of fusion whereas at the same time the activity of RhoA decreases. Finally, we also show that the knock-down of *RhoE* by RNA interference impairs down-regulation of RhoA and ROCK activities normally observed before myoblast fusion and thus inhibits myotube formation.

Results

Variation of RhoE expression during skeletal muscle cell differentiation

RhoE is ubiquitously expressed and its mRNA has been detected also in skeletal muscle contrary to *Rnd1* and *Rnd2*, the other members of this Rho family subgroup that were not observed in this tissue (13). To analyze their mRNA expression in C2C12 myoblasts we performed real-time quantitative PCR amplification using specific primer sets (22). *RhoE* mRNA was found in C2C12 myoblasts and its level was close to that of RhoA and Rac1, which are both involved in the regulation of myogenesis (Figure 1).

Rnd proteins are always bound to GTP and variations in their expression might be used to control their activities. We next analyzed RhoE mRNA and protein levels in C2C12 myoblasts induced to differentiate by replacing the growth medium (GM) with the appropriate differentiation medium (DM). At different time points after the shift to DM, cells extracts were prepared to analyze both mRNA and protein levels. The fusion process was concomitantly followed by morphological analysis of myoblast differentiation and appearance of multinucleated myoblasts. We could thus determine that fusion started between 30 to 42 hours after DM addition (Figure 2A). As shown in Figure 2B, *RhoE* mRNA gradually increased until the onset of fusion and then suddenly decreased. These variations in *RhoE* mRNA levels coincided with those of RhoE protein (Figure 2C). These results show that RhoE is upregulated at the onset of myoblast fusion.

To analyze whether RhoE participates in skeletal muscle differentiation *in vivo*, we examined its expression in a mouse model of muscle regeneration. Skeletal muscle injury was induced by injection of notexin or cardiotoxin in *tibialis anterior* muscles. Regeneration was monitored by histological analysis (Figure 2Da) and *M-cadherin* expression (Figure 2Db) four days after injection. RT-PCR amplification showed that the expression of *RhoE* and *M-cadherin* were concomitantly up-regulated during regeneration.

RhoE is required for myotube formation

To gain further insight into the role of RhoE in myogenesis, we knocked down *RhoE* expression. We generated stable C2C12 cell lines in which *RhoE* was silenced by small hairpin RNAs (C2C12 *RhoE* shRNA). We monitored the efficiency of gene silencing by Western blot analysis in five different clones (Figure 3A). In all clones RhoE protein levels relative to that of Tubulin were decreased by 50 to 80% (Figure 3B). Parental and C2C12 myoblasts expressing Firefly Luciferase specific shRNA (C2C12 *Luci* shRNA) were used as controls. Parental, C2C12 *RhoE* shRNA and *Luci* shRNA myoblasts were grown to 80% confluency and shifted to DM for 4 days. Whereas numerous myotubes were observed in the parental and control C2C12 *Luci* shRNA cells (Figure 3C, a-b), only few myotubes were visible in *RhoE* shRNA clone C2 (Figure 3C, c). Similar results were obtained with all five *RhoE* shRNA clones, demonstrating that these effects were not due to clonal variations (data not shown). Quantification of the fusion index clearly illustrates that the knock-down of *RhoE* impairs myotube formation (Figure 3D). We next examined, by Western blot analysis, whether *RhoE* silencing affected the expression of Myogenin and Troponin T, two muscle-specific proteins (Figure 3E). Their expression was similar in parental, control C2C12 *Luci* shRNA and C2C12 *RhoE* shRNA myoblasts, suggesting that induction of these genes does not require RhoE.

These data indicate that RhoE is necessary for myotube formation while dispensable for myogenesis induction.

RhoE controls myoblast elongation and alignment before fusion

We next analyzed RhoE distribution during myogenesis by indirect immuno-histochemistry using a specific, affinity-purified antibody against RhoE (Figure 4A). In proliferating C2C12 myoblasts, RhoE had a predominantly perinuclear localization (a) as in fibroblasts (23). After

DM addition, RhoE staining increased in myoblasts that were elongating and aligning before fusion (b). Once fusion has occurred, it decreased to a level similar to that of proliferating cells (d). Neither the pre-immune serum (data not shown) nor the affinity-purified antibody pre-incubated with the immune peptide (c) revealed such a staining.

We then precisely analyzed the morphological modifications occurring during myogenesis of parental and C2C12 *RhoE* shRNA myoblasts using phase contrast and scanning electron microscopy (SEM) (Figure 4B and C). During myogenesis, C2C12 myoblasts elongate and align before fusion (Figure 4B a-c and Figure 5C a-d) (24, 25). In contrast, *RhoE* knock-down prevented elongation and alignment of myoblasts which remained flat (Figure 4B d-f and Figure 5C e-h). Higher magnification analysis by SEM of the dorsal membrane revealed the presence of extensive microvilli and lamellipodia in parental C2C12 at the onset of myoblast fusion (Figure 4C d) which were absent in C2C12 *RhoE* shRNA myoblasts (Figure 4C h).

M-cadherin, a member of the Ca^{2+} -dependent cell-cell adhesion molecule family, is involved in myoblast alignment and fusion (8, 26). We thus examined M-cadherin expression and localization in C2C12 *RhoE* shRNA myoblasts (Figure 4D, a). M-cadherin was monitored at different times after DM addition. In C2C12 *RhoE* shRNA myoblasts cultured in GM, the amount of M-cadherin was similar to that of the parental C2C12 cells. M-cadherin expression decreased in C2C12 *RhoE* shRNA myoblasts grown in DM compared to parental C2C12 myoblasts (Figure 4D,a). In contrast, N-cadherin expression was comparable in C2C12 *RhoE* shRNA and parental C2C12 myoblasts (data not shown). We then analyzed M-cadherin localization by immunocytochemistry (Figure 4D, b). In control elongated and aligned C2C12 myoblasts, M-cadherin accumulated at myoblast-myotube and myotube-myotube contacts (a and b), but not in C2C12 *RhoE* shRNA cells (c and d).

Altogether, these data show that RhoE accumulates in elongated, aligned myoblasts prior fusion and its silencing impairs myoblast elongation and alignment and decreases M-cadherin expression and accumulation at intercellular contacts.

RhoE controls the down-regulation of RhoA activity at the onset of myoblast fusion

RhoE antagonizes RhoA activity (12, 20), which is highly regulated during myogenesis. Indeed, RhoA is activated and required for myogenesis induction, but its activity must be down-regulated to allow myotube formation (2, 8, 9, 27). First, we measured RhoA activity, in C2C12 myoblasts from the same kinetic as the one described in Figure 2. Figure 5 shows the crude data (A) and RhoA activity normalized to the amount of total protein (B). As previously reported, we observed an increase in RhoA-GTP level at the beginning of myogenesis. Then, RhoA-GTP content decreased and reached a minimum after 2 days in DM (i.e., at the onset of fusion) (Figure 5B). As the samples used for the experiments described in Figure 2 and 5 were similar, we reported the amount of RhoE protein onto the same graph (Figure 5B), and showed that the maximum RhoE expression correlated to the lowest RhoA activity. We next measured RhoA activity in C2C12 *RhoE* shRNA myoblasts. In control C2C12 cells, we observed a decrease in RhoA activity, 30h after DM addition, i.e., at the onset of fusion. Conversely, in C2C12 *RhoE* shRNA cells, we could not detect a decrease in RhoA activity at 30h after DM addition (Figure 5C) or at later time points. This suggests that RhoE-dependent pathways are not involved in the control of RhoA activation during myogenesis induction and that they are implicated in RhoA activity's down-regulation at the onset of myoblast fusion. To further demonstrate that RhoA activity was maintained in C2C12 *RhoE* shRNA myoblasts, we used the organization of the F-actin cytoskeleton as functional read-out (Figure 5D). After 3 days in DM, parental myoblasts showed a decrease in the number of stress fibres (Figure 5D, a and b), particularly in myotubes, as previously

reported (25). In contrast, C2C12 *RhoE* shRNA myoblasts still presented a higher amount of stress fibres, a hallmark of RhoA activation (Figure 5D, c and d).

To confirm that myoblast fusion inhibition after RhoE silencing was dependent on the continuous RhoA activation, we treated C2C12 *RhoE* shRNA myoblasts with the cell-permeable exoenzyme C3, which inactivates RhoA (28). Since RhoA activity is required for myogenesis induction (2, 3), C3 transferase was added 6h after induction of differentiation. As shown in Figure 6A, RhoA inhibition partially rescued inhibition of myoblast fusion caused by RhoE silencing. Quantification of the fusion index three days after DM addition revealed a four fold increase in myoblast fusion in C2C12 *RhoE* shRNA myoblasts treated with C3 transferase as compared to the untreated ones (Figure 6B). These data show that RhoE is responsible for the down-regulation of RhoA, a crucial step in myoblast fusion.

RhoE activates p190RhoGAP at the onset of myoblast fusion

p190RhoGAP is a RhoE effector involved in RhoE-induced inactivation of RhoA in fibroblasts (20). We thus tested whether RhoE can also interact with p190RhoGAP in C2C12 myoblasts. Immunoprecipitation using an anti-RhoE antibody was performed in extracts from C2C12 myoblasts in GM or after the indicated times in DM (Figure 7A). Endogenous p190RhoGAP co-immunoprecipitated with RhoE (Figure 8A, a), and this association increased at the onset of myoblast fusion (Figure 7A, b).

We then analyzed the GAP activity of p190RhoGAP at different time points during myoblast differentiation in parental and C2C12 *RhoE* shRNA myoblasts (Figure 7B). Activated p190RhoGAP was pulled down using GST-RhoAL63 which is locked in its GTP-bound state (29). Pulled-down samples were then immunoblotted with an anti-p190RhoGAP antibody. The activity of p190RhoGAP gradually increased in C2C12 myoblasts after DM addition. In contrast, in C2C12 *RhoE* shRNA myoblasts we did not observe any increase in the activity

of p190RhoGAP. These data support the notion that p190RhoGAP interaction with RhoE allows the increase of its activity during myoblast differentiation.

RhoE effect on myoblast fusion is also dependent on ROCK

RhoE binds to the RhoA effector ROCKI and inhibits its activity (21). Moreover, inhibition of ROCK activity is required for myoblast fusion (9, 18). We thus analyzed whether ROCK was involved in the inhibition of myoblasts fusion induced by *RhoE* silencing. We first tested whether ROCKI associated with RhoE in C2C12 myoblasts using immunoprecipitation (Figure 8A). ROCKI co-immunoprecipitated with RhoE in C2C12 myoblasts in GM or after the indicated times in DM. We next analyzed ROCK activity by assessing the phosphorylation of a ROCK substrate, the myosin binding subunit of the myosin light chain phosphatase MYPT-1, (30) (Figure 8B). As previously reported, we observed a decrease in ROCK activity during myogenesis in control cells, but not in C2C12 *RhoE* shRNA myoblasts induced to differentiate.

To gain insight into the role of ROCK in RhoE-induced myoblast fusion, we tested the effect of Y-27632, a pharmacological ROCK inhibitor. C2C12 *RhoE* shRNA myoblasts were grown in DM in the presence of Y-27632. Inhibition of ROCK partially rescued myoblast fusion in C2C12 *RhoE* shRNA cells (Figure 8C), as confirmed by quantification of the fusion index (Figure 8D). These data argue for a participation of RhoE in ROCK inhibition required for myoblast fusion.

Discussion

Unravelling the molecular mechanisms that govern myoblast fusion is important for the understanding of muscle diseases where fusion is affected or the repair process that involves adult satellite-cell fusion. Amongst the signaling pathways involved in myoblast fusion, the decrease in RhoA/ROCK activities appears to be crucial (8, 9, 18). We have searched for upstream regulators of RhoA/ROCK signaling during myoblast fusion and demonstrate here that RhoE plays an important role in their regulation and in skeletal muscle cell differentiation.

RhoE is required for myoblast fusion

Our results prove that RhoE is required for myoblast fusion in C2C12 myoblasts although is dispensable for myogenesis induction. Indeed, RhoE knock-down impairs myotube formation without altering the level of muscle-specific gene products. We report modifications in RhoE expression during myogenesis consistent with a role during myoblast fusion since its expression level, in C2C12 myoblasts, increases until the onset of myoblast fusion before resuming its basal level once fusion is well under way. Its implication in muscle differentiation is reinforced by the results we obtained in an *in vivo* model for muscle regeneration. Moreover, data of RhoE localization during myogenesis combined with the analysis of the phenotype of C2C12 myoblast in which *RhoE* was silenced, suggest that RhoE participate in myoblast elongation and alignment before fusion. The variations in RhoE expression during myogenesis are consistent with the way this molecule is regulated. Indeed, RhoE binds only weakly to GDP, has very low if any intrinsic GTPase activity and therefore exists predominantly in a GTP-bound state. RhoE is not regulated by GEFs or GAPs but rather by its expression level and post-translational modifications such as phosphorylation

(21, 31). Further studies will be required to understand how RhoE expression is controlled during myogenesis.

RhoE decreases RhoA and ROCK activities

RhoA GTPase activity is tightly controlled throughout myogenesis. At the beginning of myogenesis, RhoA is activated through an N-cadherin-mediated pathway (10, 27), and then is down-regulated at the onset of myoblast fusion (8, 18). We report here that RhoE is required for the decrease of RhoA activity during myoblast fusion. This is the first example of a regulatory pathway that negatively controls RhoA activity to allow fusion to occur. In fibroblasts, RhoE interacts with p190RhoGAP *in vitro* and increases its GAP activity toward GTP bound RhoA (20). We demonstrate here, on endogenous proteins, that the highest association between RhoE and p190RhoGAP occurs at the onset of myoblast fusion. Interestingly, C2C12 myoblasts in which *RhoE* was silenced show defects both in p190RhoGAP activation and RhoA inhibition at the onset of myoblast fusion. Finally, myoblast fusion could be partially rescued in C2C12 *RhoE* shRNA by inactivating RhoA with C3 exoenzyme. In conclusion, these data explain how RhoE, via the binding and activation of its effector p190RhoGAP antagonizes RhoA activity and participates in the induction of myoblast fusion. RhoE also inhibits RhoA signaling by binding to the RhoA-activated serine/threonine kinase ROCK, whose activity must be decreased during myogenic differentiation to allow myoblast fusion (9). Addition of the ROCK inhibitor Y-27632 partially rescued myoblast fusion in C2C12 *RhoE* shRNA myoblasts, as efficiently as C3 the exoenzyme. Moreover, Y-27632 did not strengthen the effect of C3 exoenzyme alone (data not shown), suggesting that RhoA acts through ROCK to repress myoblast fusion. Nevertheless, since the recovery of myoblast fusion with these drugs was only partial, other yet unknown RhoE effectors might participate in regulating myoblast fusion. For instance, the

RhoE effector Socius is involved in RhoE-induced disassembly of actin stress fibres (32), and Rnd2 and RhoE interact with the RhoGAP MgcRacGAP (33). Nevertheless, both Socius and MgcRacGAP are predominantly expressed in the testis, which emphasized the need to identify other skeletal muscle-specific RhoE effectors.

Spatial RhoE targeting

The mechanisms responsible for RhoE activation and function in myoblast fusion is most probably linked to its increased expression which allows its accumulation above a threshold level, thus favoring its binding to p190RhoGAP and ROCK1 that leads to the inhibition of the RhoA/ROCK pathway. Moreover, RhoE recruitment to specific plasma membrane sites might facilitate its association with p190RhoGAP and ROCK1. Indeed, in fibroblasts and epithelial cells, RhoE colocalizes with cadherins in adherens junctions (34). Although M-cadherin is involved in myoblast fusion (8), we could not detect any association of RhoE with either M-cadherin or N-cadherin in C2C12 myoblasts (data not shown). Also β 1-integrin, another transmembrane protein involved in myoblast fusion, was not associated with RhoE (data not shown) (35). In neurons, RhoE and Rnd1 interact with plexins, which are semaphorin receptors involved in axon guidance through regulation of p190RhoGAP-dependent RhoA down-regulation (28, 36). Semaphorin 4C participates in myoblast fusion (37), therefore it would be important to test whether RhoE associates with this kind of complexes in myoblasts.

RhoE/RhoA/ROCK1 signaling and myoblast fusion

Here we demonstrate for the first time that RhoE participates in skeletal muscle differentiation through the down-regulation of RhoA/ROCK signaling, an event required for myoblast fusion (8, 9). ROCK phosphorylates both the myosin binding subunit of myosin light chain phosphatase and the myosin regulatory light chain, which induces the actin-

myosin 2 interaction and promotes actin-cytoskeleton assembly and cell contractility (30, 38). When RhoA and ROCK activities are decreased, Myosin 2 activity is also reduced. In C2C12 myoblasts in which *RhoE* was silenced, stress fibres are not reduced and myoblast fusion is impaired. Interestingly, the loss of stress fibres occurs in pre-fusing myoblasts (25). Nevertheless, we could only partially rescue myoblast fusion with RhoA or ROCK inhibitors and synergy was not obtained by the addition of both (data not shown). Although we cannot rule out a possible toxicity of these drugs, this suggests the existence of other RhoE-dependent pathways controlling myoblast fusion. Indeed, we found that the inhibitor of myosin light chain kinase (MLCK) ML7 slightly increases the effect of C3 exoenzyme on the recovery of myoblast fusion in RhoE deficient myoblasts (data not shown). Myosin 2 inhibition with blebbistatin in C2C12 myoblasts in which *RhoE* was silenced also resulted in rescue of myoblast fusion (data not shown), supporting the idea that a decrease in actomyosin contraction is required for myoblast fusion. These data suggest a synergy between a RhoA/ROCK and a MLCK pathway downstream of RhoE both converging on the reduction of myosin activity. Upstream regulation of MLCK can occur through Rac1 and its effector Pak, which phosphorylates and inactivates MLCK. Moreover, there is a functional antagonistic balance between the Rho and Rac subgroups of the Rho family, and we have previously reported such a crosstalk in skeletal muscle cells (8, 17). Indeed, Rac1 signaling is required for myoblast fusion, both in *Drosophila* and in mammalian myoblasts (4-7, 17). Interestingly, our detailed examination of the membrane morphological modifications by SEM and pull-down assay (data not shown) indicate that Rac1 activity is not increased in C2C12 myoblasts in which *RhoE* was knocked down. Thus RhoE-dependent reduction of RhoA activity might also contribute to Rac1 activation. Our results establish that RhoE-dependent down-regulation of RhoA/ROCK signaling also contributes to correct functioning of M-cadherin, a protein required for myoblast fusion which is regulated by RhoA GTPase

(8). Indeed, we show that M-cadherin is down-regulated and mis-localized in myoblast in which *RhoE* was silenced and that its expression is partially rescued by the addition of RhoA or ROCK inhibitors (data not shown).

Myoblast fusion is a multi-step process in which actin cytoskeleton dynamics plays a key role. We thus propose that RhoE is an actor of myoblast fusion through the regulation of the organization of the actin cytoskeleton and M-cadherin function which in turn controls myoblast alignment and elongation.

Acknowledgments

We thank Evelyne Bloch-Gallego, Philippe Fort, Pierre Roux and Nicolas Taulet for helpfull discussions, and Keith Burridge for the RhoAL63GST expression vector. Electron scanning microscopy was performed at the Centre Regional d'Imagerie Cellulaire de Montpellier. This work was supported by the Association Française contre les Myopathies, the Agence Nationale de la Recherche, and the Association Française pour la Recherche contre le Cancer. C. G. R. was supported by INSERM and J. K. by the Ligue Nationale contre le Cancer.

Methods

Cell Culture

C2C12 mouse myoblasts were cultured as described (27). To induce differentiation, growth medium (GM) was replaced by differentiation medium (DM) consisting of DMEM/Ham's F-12 supplemented with 2% FCS. Stable cell lines derived from C2C12 myoblasts were cultured under the same conditions. Cell permeable C3 transferase (0.4 µg/ml, Cytoskeleton) or the ROCK inhibitor Y-27632 (10µM, Calbiochem) were added 6 hours after the addition of differentiation medium. Drug-containing differentiation medium was refreshed every 24 hours.

Quantification of mRNA by real-time quantitative PCR amplification

Total RNAs from myoblasts in culture were prepared using the Rneasy minikit from QIAGEN. Total RNAs from tibialis anterior muscles were extracted following the acid/guanidinium thiocyanate/phenol/chloroform method using RNable (Eurobio, France) according to the manufacturer's instructions. cDNAs were synthesized from 5 mg of total RNA using superscript II Reverse Transcriptase (Invitrogen) and random hexamer primers. The levels of the various cDNAs were determined by quantitative PCR amplification using the SYBR green I with a Light Cycler (Roche Diagnostics, sommerville, NJ). All primers used were previously described (22, 39). GAPDH mRNA was amplified as an internal control. The specificity of the primers was checked by DNA sequencing.

Gel Electrophoresis and Immunoblotting

Cell extracts were prepared as previously described (8). Protein concentration was determined with a BCA protein assay kit (Pierce Chemical, Rockford, IL). Protein extracts (20 µg) were resolved on polyacrylamide gels (12%) and transferred onto Immobilon-P membranes.

Membranes were incubated with monoclonal antibodies against RhoE (1:1000; Upstate), troponin T (1:1000; Sigma-Aldrich), myogenin (1:500; BD Biosciences PharMingen, San Diego, CA), M-cadherin (1:200, NanoTools, Munich, Germany) and α -tubulin (1:100). Membranes were processed as described previously (8).

Small hairpin RNA retroviral vector construction and establishment of stable cell lines

To suppress endogenous RhoE expression, annealed double strand oligonucleotides GATCCGTCAGAACGTGAAATGCAAAGTTCAAGAGACTTGCATTTTCACGTTCTGACCTTTTTTACGCGTG (top) and AATTCACGCGTAAAAAAGTCAGAACGTGAAATGCAAGTCTCTTGAAC TTTGCAT TTCACGTTCTGACG (bottom) were inserted into the RNAi-Ready pSIREN-RetroQ-ZsGreen vector (Clontech, BD Biosciences). Bold letters correspond to oligonucleotides 291–310 of the mouse and human RhoE cDNA sequence (NM_028810). The pSIREN-RetroQ-ZsGreen vector, which targets the firefly Luciferase, was used as a control.

Phoenix cells expressing RhoE shRNA or Luciferase shRNA were grown to collect retrovirus-containing cell-free supernatants. Infection was performed on exponentially growing C2C12 myoblasts (5×10^5 cells per 60-mm dish) by using with the use of 5 ml of viral supernatant. Positive GFP cells were selected by FACS and cloned by limited dilution. RhoE expression was assayed on five random clones for RhoE shRNA and on a pool of Luciferase shRNA expressing C2C12.

Fusion index determination

Cells growing onto 100-mm dishes were fixed in 3.7% formaldehyde in phosphate buffer (PBS) followed by a 3-min permeabilization in 0.1% Triton X-100 in PBS and saturated in PBS containing 0.1% bovine serum albumin. Nuclei were stained with Hoechst stain (0.1

µg/ml, Sigma-Aldrich) and washed with PBS. Fusion index, i.e. the number of nuclei in multinucleated myotubes divided by the total number of nuclei, was determined by the MRI Cell Image Analyser software (8). At least 7000 nuclei in each experiment were counted. Only cells with 3 nuclei or more were considered to be myotubes.

May-Grünwald Giemsa staining

Cells were washed twice with PBS, incubated with May-Grünwald diluted in PBS for 5 minutes and next with Giemsa diluted in PBS for 10 minutes.

Muscle regeneration model

Mice (male C57BL/6J, 6 week old) were anesthetized by intraperitoneal injection of pentobarbital. 20µl of 1µM notexin (Latoxan, Valence, France) or 20µl of 10µM cardiotoxin (Latoxan, Valence, France) were injected into the tibialis anterior (TA) muscles. Muscles were collected at various times after injection. Contra-lateral uninjected TA muscles were used as control. Muscles were used for hematoxylin/eosin staining and to isolate total RNA for RT-PCR.

Immunocytochemistry

Cells were fixed in 4% paraformaldehyde in PBS followed by a 2-min permeabilization in 0.1% Triton X-100 (in PBS). RhoE was stained using an affinity-purified antibody raised against an N-terminal peptide of RhoE (SQKLSSKSIMDPNQNVK) as previously described (21), and produce by Eurogentec (Seraing, Belgium). Control experiments were performed using the preimmune serum and affinity-purified anti-RhoE blocked with saturating levels of its specific peptide antigen. M-cadherin was stained using a polyclonal antibody as described (8). Anti-RhoE and anti-M-cadherin were revealed using Alexa Fluor 488-conjugated goat

anti-rabbit antibody (Molecular Probes, Invitrogen). F-actin expression was analysed using TRITC-conjugated phalloidin (Sigma-Aldrich) and nuclei were stained with Hoechst (0.1 $\mu\text{g/ml}$, Sigma-Aldrich). Images were captured with a MicroMax 1300 CCD camera (RS-Princeton Instruments, Trenton, NJ, USA) driven by the MetaMorph (v.7, Universal Imaging Corp, Westchester, PA, USA) Software. Stacks of images were captured with a piezo stepper (E662, Physik Instruments) with a Z step of 0,2 μm . Stack were then restored with Huygens deconvolution software (Scientific Volume Imaging) and restored images were viewed in 3D with MetaMorph. Images were processed using Adobe Photoshop and Adobe Illustrator.

Scanning Electron Microscopy

Parental and C2C12 *RhoE* shRNA myoblasts were grown on ThermanoxTM coverslips (Nunc) either in GM or in DM. After washing in PBS, myoblasts were fixed in PBS containing 3% glutaraldehyde for 2 hours and post-fixed with 1% OsO₄ in distilled water for 1 hour. After alcohol dehydration, myoblasts were dried in Hexamethyldisilazane (Acros Organics, New Jersey, USA) for 2 minutes, coated with Gold-palladium and observed using a Hitachi S4000 scanning microscope at 10 kV. For each condition, at least 100 cells were examined.

RhoA GTPase Activity Assay

Proliferating or differentiating C2C12 myoblasts were lysed and processed to measure the total and GTP-bound RhoA levels as described previously (8) or using the luminometry based G-LISATM Rho activation assay (Cytoskeleton, Inc).

Immunoprecipitation

C2C12 cells were lysed for 10 min in ice-cold extraction protein buffer (8). Protein extracts (1mg) were immunoprecipitated using a mouse monoclonal anti-RhoE antibody (1/1000

dilution; Upstate). Half of each immunoprecipitation was separated on a 8% polyacrylamide gels, and then transferred onto nitrocellulose. p190RhoGAP and ROCKI detection were performed using monoclonal antibody (1/250; BD Transduction Laboratories).

The other half of each immunoprecipitation was separated on a 15% polyacrylamide gel, transferred on Immobilon-P membranes and immunoblotted with a polyclonal anti-RhoE antibody.

p190 RhoGAP activity assay

RhoA L63GST (a generous gift from K. Burridge) was prepared as described (29). Cells were lysed at different times after DM addition and processed as described (28).

ROCK activity assay

Cells extracts were lysed as described (40). Protein extracts (60 μ g) were resolved on polyacrylamide gels (10%) and transferred onto Immobilon-P membranes. Membranes were probed with phospho-Mypt1 polyclonal antibody (1/1000) (Upstate) and α -tubulin (1:100).

Titles and legends to figures

Figure 1 : RhoE expression in C2C12 myoblasts

RhoA, Rac1 and RhoE cDNA levels relative to GAPDH were determined by quantitative RT-PCR amplification. The graph is representative of three independent experiments.

Figure 2 : RhoE expression during C2C12 myoblasts differentiation

C2C12 myoblasts grown in GM or in DM for the indicated times were simultaneously processed for the analysis of the fusion process (A) and for mRNA (B) and protein extracts preparation (C).

A) Phase contrast images of myoblasts and myotubes during the differentiation process. Bar: 20 μ m.

B) The graph shows the RhoE cDNA levels relative to the GAPDH level in the same sample at the indicated periods, determined by quantitative RT-PCR amplification. Data are the mean \pm SEM of five independent experiments.

C) Proteins extracts (50 μ g/well) from C2C12 myoblasts, collected at the indicated times, were immunoblotted for the assessment of RhoE and α -Tubulin expression. The histogram represents the quantification of RhoE normalized for the amount of α -Tubulin. The histogram shows the quantification of the two bands but similar variations have been observed for each of these bands (data not shown).

D) a) Serial sections from control (a) and injured TA muscles four days after notexin injection (b) were stained with haematoxylin and eosin. Bar : 100 μ m. b) Expression of M-cadherin and RhoE determined by quantitative RT-PCR amplification after normalization to GAPDH four days after notexin or cardiotoxin injection. The graph is representative of three independent experiments.

Figure 3: Inhibition of *RhoE* expression by RNA interference prevents myotube formation

A) *Luciferase* and *RhoE* shRNAs were delivered in C2C12 myoblasts by retroviral infection. Cells were selected and clones of resistant cells were analyzed for the expression of *RhoE* and α -Tubulin by immunoblot analysis.

B) The histogram represents the quantification of *RhoE* normalized for the amount of α -Tubulin in the different clones. Data are the mean \pm SEM of three independent experiments. The histogram shows the quantification of the two bands but similar variations have been observed for each of these bands (data not shown).

C) May-Grünwald Giesma stain of parental (panel a), control C2C12 *Luci* shRNA (panel b) and C2C12 *RhoE* shRNA myoblasts (clone B, panel c) after 4 days in DM. Bar, 50 μ m.

D) The histogram represents the fusion index calculated at the indicated times after DM addition for parental, control C2C12 *Luci* shRNA and C2C12 *RhoE* shRNA myoblasts (clone B). Data are the mean \pm SEM of three independent experiments: at least 7000 nuclei were counted per experiment.

E) Cell lysates (20 μ g/well) of parental, control C2C12 *Luci* shRNA and C2C12 *RhoE* shRNA myoblasts cultured in GM or DM for the indicated periods were assessed by Western blot analysis for the expression of Myogenin, Troponin T and α -Tubulin. The histogram represents the quantification of Myogenin (black) and Troponin T (grey) normalized for the amount of α -Tubulin from four independent experiments.

Figure 4: Inhibition of *RhoE* expression by RNA interference prevents myoblast elongation and alignment

A) RhoE localization analyzed by indirect immunofluorescence in proliferating C2C12 myoblasts (a) or after 30 (b) or 96 hours (d) in DM. Staining obtained with the affinity-purified RhoE antibody pre-incubated with the immune peptide (c). Bar : 10 μ m.

B) Phase contrast images of parental (a-c) and C2C12 *RhoE* shRNA myoblasts (d-f) cultured in GM or DM for the indicated periods. Bar : 10 μ m.

C) Scanning electron micrographs of parental and C2C12 *RhoE* shRNA myoblasts cultured in GM or DM for the indicated periods. Bar : 10 μ m.

D) a : Protein extracts (20 μ g/well) from parental and C2C12 *RhoE* shRNA myoblasts collected at the indicated periods were immunoblotted for M-cadherin and α -Tubulin expression. The histogram represents the quantification of M-cadherin normalized for the amount of α -Tubulin in three independent experiments. b : M-cadherin localization in parental (a-b) and C2C12 *RhoE* shRNA (c-d) myoblasts analyzed by indirect immunofluorescence. Shown are deconvolved images of M-cadherin (green) and DNA staining (blue). Bar : 10 μ m.

Figure 5: RhoE downregulates RhoA activity

A) The level of GTP-bound RhoA was measured using GST fused to the Rho-binding domain of the RhoA effector Rhotekin (GST-RBD) in lysates obtained from C2C12 cells in GM or DM from the same kinetic as the one described in Figure 2. RhoA was detected by immunoblotting. Data are representative of three independent experiments.

B) RhoA GTPase activity normalized to the amount of total protein was calculated from panel A and plotted with the RhoE protein levels in cell extracts from the same kinetic (shown in Figure 2B).

C) The level of GTP-bound RhoA was measured in lysates obtained from parental and C2C12 *RhoE* shRNA myoblasts that were in GM or DM and collected at the indicated times. Data are representative of three independent experiments.

D) Parental and C2C12 *RhoE* shRNA myoblasts were fixed after 3 days in DM and stained for F-actin (panels a and c). Overlay of F-actin (red) and DNA staining (blue) are shown in panels b and d. Bar : 10 μ m.

Figure 6: RhoA inhibition partially rescues myoblast fusion

Control C2C12 *Luci* and *RhoE* shRNA myoblasts were induced to differentiate by replacing the GM with the appropriate DM. 6 hours later C3 transferase was added if appropriate. DM with or without C3 transferase was replaced every 24 hours.

A) Images of control C2C12 *Luci* shRNA (panel a) and C2C12 *RhoE* shRNA myoblasts (panel b) after 4 days in DM or C2C12 *RhoE* shRNA myoblasts after 4 days in DM containing C3 transferase (panel c). Bar, 50 μ m.

B) The histogram represents the fusion index calculated 96 hours after DM addition for control C2C12 *Luci* and *RhoE* shRNA C2C12 myoblasts treated, or not, with C3 transferase. Data are the mean \pm SEM of three independent experiments, where at least 3000 nuclei/experiment were counted.

Figure 7: RhoE binds to p190RhoGAP and regulates its activity at the onset of the fusion process

A) a) Cell lysates of C2C12 myoblasts cultured in GM or at the indicated times after DM addition were immunoprecipitated using an anti-RhoE antibody and immunoblotted for the presence of p190RhoGAP and RhoE. -, without anti-RhoE antibody; +, with anti-RhoE

antibody. b) The histogram shows the quantification of p190RhoGAP associated with RhoE. Data are the mean +/- SEM of three independent experiments.

B) Control and *RhoE* shRNA C2C12 myoblasts cultured in GM or at different times after DM were lysed and subjected to pull-down analysis with GST-RhoAL63. The precipitated material and total lysates were analyzed for p190RhoGAP levels by immunoblotting. Three independent experiments were analyzed by densitometry. The histogram represents the GAP activity normalized to the total protein content.

Figure 8: ROCK inhibition partially rescues myoblast fusion in RhoE deficient cells

A) Cell lysates of C2C12 myoblasts cultured in GM or at different times after DM addition were immunoprecipitated using an anti-RhoE antibody and immunoblotted to assess the presence of ROCK I and RhoE. -, without anti-RhoE antibody; +, with anti-RhoE antibody.

B) Phospho-MYPT-1 and α -Tubulin levels were analyzed in total lysates by immunoblotting from control and C2C12 *RhoE* shRNA myoblasts cultured in GM or at different times after DM addition. The histogram shows the quantification of MYPT-1 phosphorylation normalized to the total protein content. Data are the mean +/- SEM of three independent experiments.

C) Images of C2C12 *RhoE* shRNA myoblasts after 4 days in DM (panel a) or DM containing Y-27632 (panel b). Bar, 50 μ m.

D) The histogram represents the fusion index calculated at the indicated times after DM addition for control C2C12 *Luci* and *RhoE* shRNA myoblasts treated or not with Y-27632. Data are the mean +/- SEM of three independent experiments, where at least 3000 nuclei/experiment were counted.

References

1. Jaffe AB, Hall A. Rho GTPases: biochemistry and biology. *Annu Rev Cell Dev Biol.* 2005;21:247-269.
2. Carnac G, Primig M, Kitzmann M, Chafey P, Tuil D, Lamb N, Fernandez A. RhoA GTPase and serum response factor control selectively the expression of MyoD without affecting myf5 in mouse myoblasts [In Process Citation]. *Mol Biol Cell.* 1998;9(7):1891-1902.
3. Meriane M, Roux P, Primig M, Fort P, Gauthier-Rouviere C. Critical activities of Rac1 and Cdc42Hs in skeletal myogenesis: antagonistic effects of JNK and p38 pathways. *Mol Biol Cell.* 2000;11(8):2513-2528.
4. Luo L, Liao YJ, Jan LY, Jan YN. Distinct morphogenetic functions of similar small GTPases: *Drosophila* Drac1 is involved in axonal outgrowth and myoblast fusion. *Genes Dev.* 1994 Aug 1;8(15):1787-1802.
5. Hakeda-Suzuki S, Ng J, Tzu J, Dietzl G, Sun Y, Harms M, Nardine T, Luo L, Dickson BJ. Rac function and regulation during *Drosophila* development. *Nature.* 2002 Mar 28;416(6879):438-442.
6. Fernandes JJ, Atreya KB, Desai KM, Hall RE, Patel MD, Desai AA, Benham AE, Mable JL, Straessle JL. A dominant negative form of Rac1 affects myogenesis of adult thoracic muscles in *Drosophila*. *Dev Biol.* 2005 Sep 1;285(1):11-27.
7. Erickson MR, Galletta BJ, Abmayr SM. *Drosophila* myoblast city encodes a conserved protein that is essential for myoblast fusion, dorsal closure, and cytoskeletal organization. *J Cell Biol.* 1997 Aug 11;138(3):589-603.
8. Charrasse S, Comunale F, Grumbach Y, Poulat F, Blangy A, Gauthier-Rouviere C. RhoA GTPase regulates M-cadherin activity and myoblast fusion. *Mol Biol Cell.* 2006 Feb;17(2):749-759.
9. Castellani L, Salvati E, Alema S, Falcone G. Fine regulation of RhoA and Rock is required for skeletal muscle differentiation. *J Biol Chem.* 2006 Jun 2;281(22):15249-15257.
10. Lovett FA, Gonzalez I, Salih DA, Cobb LJ, Tripathi G, Cosgrove RA, Murrell A, Kilshaw PJ, Pell JM. Convergence of Igf2 expression and adhesion signalling via RhoA and p38 MAPK enhances myogenic differentiation. *J Cell Sci.* 2006 Dec 1;119(Pt 23):4828-4840.
11. Foster R, Hu KQ, Lu Y, Nolan KM, Thissen J, Settleman J. Identification of a novel human Rho protein with unusual properties: GTPase deficiency and in vivo farnesylation. *Mol Cell Biol.* 1996 Jun;16(6):2689-2699.
12. Guasch RM, Scambler P, Jones GE, Ridley AJ. RhoE regulates actin cytoskeleton organization and cell migration. *Mol Cell Biol.* 1998 Aug;18(8):4761-4771.
13. Nobes CD, Lauritzen I, Mattei MG, Paris S, Hall A, Chardin P. A new member of the Rho family, Rnd1, promotes disassembly of actin filament structures and loss of cell adhesion. *J Cell Biol.* 1998 Apr 6;141(1):187-197.
14. Chardin P. Function and regulation of Rnd proteins. *Nat Rev Mol Cell Biol.* 2006 Jan;7(1):54-62.
15. Meriane M, Charrasse S, Comunale F, Mery A, Fort P, Roux P, Gauthier-Rouviere C. Participation of small GTPases Rac1 and Cdc42Hs in myoblast transformation. *Oncogene.* 2002;21(18):2901-2907.
16. Nolan KM, Barrett K, Lu Y, Hu KQ, Vincent S, Settleman J. Myoblast city, the *Drosophila* homolog of DOCK180/CED-5, is required in a Rac signaling pathway utilized for multiple developmental processes. *Genes Dev.* 1998 Nov 1;12(21):3337-3342.

17. Charrasse S, Comunale F, Fortier M, Portales-Casamar E, Debant A, Gauthier-Rouviere C. M-cadherin activates Rac1 GTPase through the Rho-GEF trio during myoblast fusion. *Mol Biol Cell*. 2007 May;18(5):1734-1743.
18. Nishiyama T, Kii I, Kudo A. Inactivation of Rho/ROCK signaling is crucial for the nuclear accumulation of FKHR and myoblast fusion. *J Biol Chem*. 2004 Nov 5;279(45):47311-47319.
19. Chardin P. GTPase regulation: getting aRnd Rock and Rho inhibition. *Curr Biol*. 2003 Sep 16;13(18):R702-704.
20. Wennerberg K, Forget MA, Ellerbroek SM, Arthur WT, Burr ridge K, Settleman J, Der CJ, Hansen SH. Rnd proteins function as RhoA antagonists by activating p190 RhoGAP. *Curr Biol*. 2003 Jul 1;13(13):1106-1115.
21. Riento K, Guasch RM, Garg R, Jin B, Ridley AJ. RhoE binds to ROCK I and inhibits downstream signaling. *Mol Cell Biol*. 2003 Jun;23(12):4219-4229.
22. Brazier H, Stephens S, Ory S, Fort P, Morrison N, Blangy A. Expression profile of RhoGTPases and RhoGEFs during RANKL-stimulated osteoclastogenesis: identification of essential genes in osteoclasts. *J Bone Miner Res*. 2006 Sep;21(9):1387-1398.
23. Riento K, Totty N, Villalonga P, Garg R, Guasch R, Ridley AJ. RhoE function is regulated by ROCK I-mediated phosphorylation. *Embo J*. 2005 Mar 23;24(6):1170-1180.
24. Burattini S, Ferri P, Battistelli M, Curci R, Luchetti F, Falcieri E. C2C12 murine myoblasts as a model of skeletal muscle development: morpho-functional characterization. *Eur J Histochem*. 2004 Jul-Sep;48(3):223-233.
25. Swailes NT, Knight PJ, Peckham M. Actin filament organization in aligned pre-fusion myoblasts. *J Anat*. 2004 Nov;205(5):381-391.
26. Kaufmann U, Kirsch J, Irintchev A, Wernig A, Starzinski-Powitz A. The M-cadherin catenin complex interacts with microtubules in skeletal muscle cells: implications for the fusion of myoblasts. *J Cell Sci*. 1999 Jan;112 (Pt 1):55-68.
27. Charrasse S, Meriane M, Comunale F, Blangy A, Gauthier-Rouviere C. N-cadherin-dependent cell-cell contact regulates Rho GTPases and beta-catenin localization in mouse C2C12 myoblasts. *J Cell Biol*. 2002 Sep 2;158(5):953-965.
28. Barberis D, Casazza A, Sordella R, Corso S, Artigiani S, Settleman J, Comoglio PM, Tamagnone L. p190 Rho-GTPase activating protein associates with plexins and it is required for semaphorin signalling. *J Cell Sci*. 2005 Oct 15;118(Pt 20):4689-4700.
29. Garcia-Mata R, Wennerberg K, Arthur WT, Noren NK, Ellerbroek SM, Burr ridge K. Analysis of activated GAPs and GEFs in cell lysates. *Methods Enzymol*. 2006;406:425-437.
30. Kimura K, Ito M, Amano M, Chihara K, Fukata Y, Nakafuku M, Yamamori B, Feng J, Nakano T, Okawa K, Iwamatsu A, Kaibuchi K. Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase). *Science*. 1996 Jul 12;273(5272):245-248.
31. Hansen SH, Zegers MM, Woodrow M, Rodriguez-Viciana P, Chardin P, Mostov KE, McMahon M. Induced expression of Rnd3 is associated with transformation of polarized epithelial cells by the Raf-MEK-extracellular signal-regulated kinase pathway. *Mol Cell Biol*. 2000 Dec;20(24):9364-9375.
32. Katoh H, Harada A, Mori K, Negishi M. Socius is a novel Rnd GTPase-interacting protein involved in disassembly of actin stress fibers. *Mol Cell Biol*. 2002 May;22(9):2952-2964.

33. Naud N, Toure A, Liu J, Pineau C, Morin L, Dorseuil O, Escalier D, Chardin P, Gacon G. Rho family GTPase Rnd2 interacts and co-localizes with MgcRacGAP in male germ cells. *Biochem J.* 2003 May 15;372(Pt 1):105-112.
34. Rubenstein NM, Chan JF, Kim JY, Hansen SH, Firestone GL. Rnd3/RhoE induces tight junction formation in mammary epithelial tumor cells. *Exp Cell Res.* 2005 Apr 15;305(1):74-82.
35. Schwander M, Leu M, Stumm M, Dorchie OM, Ruegg UT, Schittny J, Muller U. Beta1 integrins regulate myoblast fusion and sarcomere assembly. *Dev Cell.* 2003 May;4(5):673-685.
36. Oinuma I, Katoh H, Harada A, Negishi M. Direct interaction of Rnd1 with Plexin-B1 regulates PDZ-RhoGEF-mediated Rho activation by Plexin-B1 and induces cell contraction in COS-7 cells. *J Biol Chem.* 2003 Jul 11;278(28):25671-25677.
37. Ko JA, Gondo T, Inagaki S, Inui M. Requirement of the transmembrane semaphorin Sema4C for myogenic differentiation. *FEBS Lett.* 2005 Apr 11;579(10):2236-2242.
38. Katoh K, Kano Y, Amano M, Onishi H, Kaibuchi K, Fujiwara K. Rho-kinase-mediated contraction of isolated stress fibers. *J Cell Biol.* 2001 Apr 30;153(3):569-584.
39. Charrasse S, Comunale F, Gilbert E, Delattre O, Gauthier-Rouviere C. Variation in cadherins and catenins expression is linked to both proliferation and transformation of Rhabdomyosarcoma. *Oncogene.* 2004 Mar 25;23(13):2420-2430.
40. Wu Y, Erdodi F, Muranyi A, Nullmeyer KD, Lynch RM, Hartshorne DJ. Myosin phosphatase and myosin phosphorylation in differentiating C2C12 cells. *J Muscle Res Cell Motil.* 2003;24(8):499-511.




Figure 1




Figure 2










Figure 3

A**B**

hal-00346781, version 1 - 20 Jan 2010
 C2C12

**D****Figure 4**




Figure 5




Figure 6




Figure 7




Figure 8